KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.

Felice Strollo, Giuseppina Guarino, Ersilia Satta, Sandro Gentile

Diabetes Ther 15(9) 1855-1860

PMID39085745
PMCIDPMC11330428
DOI10.1007/s13300-024-01624-4
发表日期2024-07-31
摘要

摘要

Tirzepatide is the first ever once-weekly, injectable gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) dual agonist approved by the European Medicines Agency for type 2 diabetes. The efficacy and safety of tirzepatide have been evaluated in five global, randomized, double-blind or open-label, phase 3 studies which enrolled over 7000 people living with type 2 diabetes, across various stages of disease and with different characteristics at baseline. In this short commentary we report the salient data of the most recent trials on tirzepatide and GLP-1 receptor agonists from a clinical point of view, with the aim of highlighting similarities and mutual differences.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。